The Use of Bacterial Lysate for the Prevention of Wheezing Episodes in Preschool Children: A Cost-Utility Analysis
- PMID: 36243402
- DOI: 10.1016/j.jaip.2022.09.039
The Use of Bacterial Lysate for the Prevention of Wheezing Episodes in Preschool Children: A Cost-Utility Analysis
Abstract
Background: Although increasing recent evidence has shown the efficacy of bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations in pediatric patients, evidence of its cost-effectiveness in preschool patients is scarce.
Objectives: To evaluate the cost-utility of bacterial lysate therapy as an add-on to standard care of preschool children with recurrent wheezing.
Methods: To achieve the objectives of the study, we used a Markov simulation model with 3 mutually exclusive nonabsorbent states (regular Markov chain). Effectiveness parameters were obtained from a recent systematic review of the literature with meta-analyses (5 randomized controlled trials, 433 children). Cost data were obtained from hospital bills and from the national manual of drug prices in Colombia. The study was carried out from the perspective of the national health care system in Colombia. The main outcome of the model was quality-adjusted life-years. To assess the robustness of the model's results, we performed deterministic and probabilistic sensitivity analysis.
Results: Compared with standard care, bacterial lysate add-on therapy to standard care was associated with lower overall treatment costs (US $694.03 vs $830.71 average cost per patient) and the greatest gain in QALYs (0.9211 vs 0.9154 QALYs on average per patient), thus showing dominance.
Conclusions: In Colombia, compared with standard care, bacterial lysate add-on therapy to standard care for treating preschool children with recurrent wheezing is a dominant strategy because it showed a greater gain in QALYs at lower total treatment costs.
Keywords: Bacterial lysate; Cost-effectiveness; Preschool children; Recurrent wheezing.
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis.Eur Respir Rev. 2020 Nov 27;29(158):190175. doi: 10.1183/16000617.0175-2019. Print 2020 Dec 31. Eur Respir Rev. 2020. PMID: 33246991 Free PMC article.
-
Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.J Asthma. 2013 May;50(4):410-8. doi: 10.3109/02770903.2013.767909. Epub 2013 Mar 5. J Asthma. 2013. PMID: 23356720
-
Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country.Pediatr Pulmonol. 2021 Sep;56(9):2987-2996. doi: 10.1002/ppul.25541. Epub 2021 Jun 24. Pediatr Pulmonol. 2021. PMID: 34143576
-
Advantage of inhaled corticosteroids as additional therapy to systemic corticosteroids for pediatric acute asthma exacerbations: a cost-effectiveness analysis.J Asthma. 2020 Sep;57(9):949-958. doi: 10.1080/02770903.2019.1628254. Epub 2019 Jun 17. J Asthma. 2020. PMID: 31164017
-
The use of ipratropium bromide for treating moderate to severe asthma exacerbations in pediatric patients in an emergency setting: A cost-effectiveness analysis.Pediatr Pulmonol. 2021 Dec;56(12):3706-3713. doi: 10.1002/ppul.25648. Epub 2021 Sep 2. Pediatr Pulmonol. 2021. PMID: 34473916
Cited by
-
OM-85, a Bacterial Lysate, Reduces Pulmonary Nodule Malignant Probability: A Retrospective Study.Clin Respir J. 2025 Jul;19(7):e70109. doi: 10.1111/crj.70109. Clin Respir J. 2025. PMID: 40692186 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical